Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2023-05-15 00:00:00 ET · period of report 2023-05-11 · accession 0001209191-23-029509 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-05-15 | 2023-05-11 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | S - Sale+OE | $94.67 | -30.0K | 431.8K | -6% | -$2.84M |
| D | 2023-05-15 | 2023-05-11 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $67.81 | +30.0K | 456.2K | +7% | +$2.03M |
| D | 2023-05-15 | 2023-05-11 | BMRN | BIENAIME JEAN JACQUES | CEO, Dir | M - OptEx | $0.00 | -30.0K | 39.1K | -43% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-11 | S | D | 5,561 | $95.22 | 426,213 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F3) The price in column 4 is the weighted average price. The price actually received ranged from $94.94 to $95.39. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 2 | Common | Common Stock | 2023-05-11 | M | A | 30,000 | $67.81 | 456,213 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. |
| 3 | Common | Common Stock | 2023-05-11 | S | D | 24,439 | $94.55 | 431,774 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F2) The price in column 4 is the weighted average price. The price actually received ranged from $93.935 to $94.93. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 4 | Derivative | Stock Option (Right to Buy Common Stock) | 2023-05-11 | M | D | 30,000 | $0.00 | 39,130 | D | $67.81 · 2013-11-15 to 2023-05-14 | 30,000 Common Stock | (F1) Trade made pursuant to a 10b5-1 plan executed on November 17, 2022. (F4) Reflects the number of options outstanding after the transactions from this specific stock option grant. |